Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects-Reference-Cited by-同舟云学术

Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects

Published:2017-11 Issue:11 Volume:39 Page:2260-2275.e1
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Tomkinson Helen,McBride Eileen,Martin Paul,Lisbon Eleanor,Dymond Angela W.,Cantarini Mireille,So Karen,Holt David

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference21 articles.

1. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor;Yeh;Clin Cancer Res,2007

2. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer;Banerji;Clin Cancer Res,2010

3. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice;Denton;Cancer Chemother Pharmacol,2011

4. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

5. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site;Platz;Mol Oncol,2008

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selumetinib—A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis;Indian Dermatology Online Journal;2024-06-26

2. A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-04-09

3. Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas;Neuro-Oncology Advances;2024-01-01

4. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males;Advances in Therapy;2023-01-11

5. A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib;Clinical Therapeutics;2022-04